ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.630,44
0,41%
S&P 500
5.487,03
0,25%
US Dollar vs BRL
5,4413
0,00%
Bitcoin
65.373,65
0,36%
Brent Oil
84,785
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Selecta Biosciences Inc (SELB)

  7. Selecta Biosciences Inc (SELB) Notícias

SELB

Selecta Biosciences (SELB)

Selecta Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SELB
DataHoraFonteTítuloCódigoCompanhia
17/06/202408:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SELBSelecta Biosciences Inc
08/05/202408:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SELBSelecta Biosciences Inc
26/04/202410:09Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SELBSelecta Biosciences Inc
26/04/202408:57Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SELBSelecta Biosciences Inc
19/04/202417:49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SELBSelecta Biosciences Inc
10/04/202422:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SELBSelecta Biosciences Inc
10/04/202417:29Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SELBSelecta Biosciences Inc
07/03/202409:08Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SELBSelecta Biosciences Inc
14/02/202414:38Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SELBSelecta Biosciences Inc
31/01/202418:30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SELBSelecta Biosciences Inc
23/01/202418:05Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SELBSelecta Biosciences Inc
12/01/202418:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SELBSelecta Biosciences Inc
08/01/202409:10GlobeNewswire Inc.Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for AutoimmunityNASDAQ:SELBSelecta Biosciences Inc
08/01/202409:00GlobeNewswire Inc.Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia GravisNASDAQ:SELBSelecta Biosciences Inc
08/12/202318:28Edgar (US Regulatory)Form 8-A12G - Registration of securities [Section 12(g)]NASDAQ:SELBSelecta Biosciences Inc
04/12/202318:39Edgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]NASDAQ:SELBSelecta Biosciences Inc
04/12/202302:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SELBSelecta Biosciences Inc
01/12/202318:43Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SELBSelecta Biosciences Inc
01/12/202310:31Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SELBSelecta Biosciences Inc
22/11/202318:39Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:SELBSelecta Biosciences Inc
13/11/202310:05GlobeNewswire Inc.Selecta Biosciences Announces Merger with Cartesian TherapeuticsNASDAQ:SELBSelecta Biosciences Inc
31/10/202317:03GlobeNewswire Inc.Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner SobiNASDAQ:SELBSelecta Biosciences Inc
25/10/202318:29Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SELBSelecta Biosciences Inc
17/08/202308:00GlobeNewswire Inc.Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 EconomicsNASDAQ:SELBSelecta Biosciences Inc
14/08/202308:00Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:SELBSelecta Biosciences Inc
16/06/202317:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SELBSelecta Biosciences Inc
13/06/202311:28Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SELBSelecta Biosciences Inc
12/06/202317:31Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SELBSelecta Biosciences Inc
31/05/202308:00GlobeNewswire Inc.Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of RheumatologyNASDAQ:SELBSelecta Biosciences Inc
04/05/202308:37Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SELBSelecta Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SELB

Seu Histórico Recente

BIT
P20QO8
NLBNPIT20QO8 20240920 520
ASX
TGN
Tungsten Mining NL
BIT
P1U654
BNP Paribas Issuance
BIT
P1DFX6
BNP Paribas Issuance
BIT
P1ORT6
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados